Vida Ventures Closes $825 Million Vida III Fund to Advance Transformative Biomedical Innovations
On June 24. 2021 , (BUSINESS WIRE) reported, Vida Ventures (“Vida”), a next-generation life sciences venture firm, announced today the closing of Vida Ventures III, L.P. (“Vida III”) on $825 million in an oversubscribed fund. Vida, founded in 2017, now has over $1.7 billion of assets under management.
“We embrace a flexible mandate that allows us to dynamically source the most promising opportunities regardless of geography, stage of development or financing”
Vida III will build upon the success of Vida’s first two funds and continue its investment approach of identifying and investing in transformative biomedical innovations with the potential to meaningfully impact patients. The capital was raised globally from existing and new blue-chip institutional investors, including top-tier endowments and foundations, sovereign wealth funds, pensions, financial institutions, family offices, fund-of-funds and notable individuals.
Vida has assembled an industry-leading team, including world-class scientific and strategic advisors, who have developed over 25 separate, novel drugs approved by the U.S. Food and Drug Administration. Vida represents depth and breadth of experience in biotechnology, pharmaceuticals, academia, entrepreneurship and investing. Vida’s leadership includes:
Arie Belldegrun, MD, FACS – Co-Founder and Senior Managing Director
Helen S. Kim, MBA – Senior Managing Director
Arjun Goyal, MD, MPhil, MBA – Co-Founder and Managing Director
Stefan Vitorovic, MS, MBA – Co-Founder and Managing Director
Rajul Jain, MD – Managing Director
Jean-Philippe Kouakou-Zebouah, MBA – Chief Financial Officer and Chief Operating Officer
Read full article HERE
